Introduction
The experience of acute mountain sickness (AMS) at a general hospital lying at an altitude of 1370 m in Kathmandu, Nepal, is now described.
There are a number of limitations on the value of the observations. Firstly, patients are not seen at high altitude, but only after evacuation, generally from the Everest Base Camp route by which heights of anything up to 5800 m may be achieved without mountaineering or even scrambling. Secondly, patients are of such diverse nationality and language that history-taking is often difficult or impossible. Thirdly, Shanta Bhawan is a busy service-orientated mission hospital in which it is hard to find time for adequate observational and analytical work.
From the epidemiological point of view, the figures presented suffer from a further limitation, namely that there is no adequate information available regarding the total number of persons going to altitude and their distribution with regard to age, sex, nationality and rate of ascent. In other words, the epidemiological denominator is missing. An analysis of 278 trekkers passing through Pheriche on the Everest route in one month was attempted by Hackett, Rennie and Levine (1976) . This put the overall incidence of AMS at 53%°, although it is possible that the criteria for diagnosis were insufficiently strict. The incidence of life-threatening disease was 4-3y. of the total group.
The data given here are intended to represent only one individual's experience of severe AMS under the conditions described. As an aid to true epidemiological work in the future, it is suggested that there is a need for agreement on a 'unit of altitude stress' that will take into account both the absolute altitude achieved and the rate at which it is reached.
Definitions
AMS may conveniently be divided into benign and malignant forms. The symptoms and signs of benign AMS are well known, and are listed in Table 1 . Peripheral oedema and retinal haemorrhages (Table 2) This will help to emphasize the language difficulty in studying these trekkers. The proportion of Japanese is probably grossly underestimated since in many cases communication was so poor as to prevent determination of the history at all. There are only 2 Nepalese: one was a lady who went on pilgrimage to the shrine of Muktinath, which lies at about 4250 m. She became unconscious 5 min after arrival at the shrine, and even after air evacuation she was stuporous, her arms were rigid and her legs flaccid and she remained incontinent of urine for about 10 days. The second Nepalese was a Sherpa who developed cerebral oedema at about 7000 m on the 1973 Italian Everest expedition. Since then Clarke and Duff (1976) have reported 2 more cases in Sherpas on an expedition at about 7300 m. It is worth noting that Sherpas do not suffer from any form of mountain sickness when returning to their homes in the Solo-Khumbu at 3350-4900 m, unlike the natives of the high Andes and the residents of Leadville, Colorado, who frequently suffer re-entry disease, especially pulmonary oedema. This may be connected with the fact that chronic mountain sickness (Monge's disease) has never been reported from the Himalayas, and the observation of Morpurgo et al. (1976) that Sherpas achieve a high affinity of the blood for oxygen without increasing the haemoglobin content of the blood. In fact they appear to become anaemic by normal standards when they descend to lower altitudes. The authors consider this to represent a genetic adaptation to hypoxia, but have not been able to discover a physiological basis for it.
The Austrian, Swiss and German patients included several experienced Alpine guides, who had no idea that Himalayan altitudes held dangers for them. Age distribution (Table 3 ) This is unremarkable except in so far as it draws attention to the fact that no age group is immune to acute mountain sickness. Hackett et al. (1976) showed, however, that younger trekkers are more at risk from mountain sickness than older people, even if adjustment is made for a slower rate of ascent.
Sex distribution
There were 33 males (84 6%). This probably reflects the sex distribution of the trekking population, which was 71 % male in the paper of Hackett et al. (1976) . Blood pressure (150/70 mmHg) was lower than previously recorded levels, X-ray showed some cardiomegaly as well as pulmonary oedema, ECG showed incomplete left bundle branch block and the serum aspartate aminotransferase was very high. All the factors seemed to point to cardiogenic pulmonary oedema, and he was accordingly given digitalis. However, he deteriorated and died the day after admission and post-mortem revealed severe pulmonary oedema, thrombosis of several major branches of the pulmonary arteries and no evidence of myocardial infarction in spite of moderate coronary artery arteriosclerosis. It seems that he suffered from HAPO, the only uncertainty being the pulmonary arterial thrombosis, a feature that had been noted in a previous post-mortem (Houston and Dickinson, 1975) .
Features of cerebral oedema
HACO is very often associated with HAPO, and it may even be that some degree of pulmonary oedema is necessary to provide the extra degree of hypoxaemia that triggers HACO. As already mentioned, apparently 'pure' HACO cases may have had some HAPO that was missed in the mountains and had resolved by the time of admission to hospital. Table 6 shows the commonest feature of HACO. Probably the heel-toe walking, finger-nose, and Romberg's tests are the most useful in detecting early disease. Papilloedema is often mild or absent. Transient hemiparesis has been noted in association with HACO, but it is important to realize that a cerebrovascular accident may occur at altitude independent of HACO, as happened to a Sherpa on a recent Everest expedition. Some less common findings are listed in Table 7 . As an illustration of the development of HACO, Fig. 1 shows the progression of events in a 31-yearold male Norwegian patient on an altitude/time diagram. The patient himself drew the rough graph from which this figure was adapted. He suffered some diarrhoea and vomiting in the first few days of his trek, noted Cheyne-Stokes breathing at Namche Bazaar 3450 m, headache at Thyangboche 4200 m getting worse at Dingboche 4250 m on the fifth day with nausea and some unsteadiness on the feet. However, he pressed on to Gorakshep 5650 m and there collapsed with such severe weakness and inco-ordination that he could no longer walk. Had he remained at Dingboche, it is almost certain that he could have descended on his own feet, but the extra day's ascent caused him to be so helpless as to need to be carried down on a Sherpa's back using portable oxygen, and then air evacuation to Kathmandu. On arrival he was alert and coherent, but grossly ataxic and had mild papilloedema. Full recovery took about 3 days. He was indignant about the illness, because he claimed that he had followed the recommendations of the Himalayan Rescue Association regarding the rate of ascent and the need for spending 2 nights at the same altitude at about 3650 or 4250 m. This was so, but he had ignored the advice not to go higher if suffering symptoms of altitude sickness, and this had been his undoing.
Treatment
Descent to a lower altitude is clearly the mainstay of treatment. The current recommendation in Nepal, no matter how serious the case, is to start evacuation by foot. If the patient is able to walk he may do so, otherwise he must be carried on a porter's back or on a yak. This is generally simpler on mountain trails than using a stretcher. If necessary, the descent should not be delayed till morning, but undertaken by moonlight or torchlight. Using these methods it is rarely necessary to go to the expense of helicopter evacuation, which in any case may be much delayed because of slow communications. Even if a helicopter is summoned, arrangements should be made for foot evacuation in the meanwhile, and the helicopter service advised of various possible picking-up points. Oxygen may be life-saving temporarily, but should not be regarded as a substitute for descent.
The role of diuretics has been questioned on the grounds that the patients are often already dehydrated. However, it seems reasonable to accept a degree of peripheral dehydration for the sake of drawing fluid out of the lungs and brain, provided a careful watch is kept for evidence of hypovolaemia.
Agents for reducing cerebral oedema include corticosteroids, such as betamethasone and dexamethasone, and osmotic agents such as hypertonic glycerol, mannitol and urea. It is generally difficult to separate the effects of these agents from the effect of evacuation, and there is little direct evidence that they are of value.
Morphine has been used for the treatment of HAPO with apparent benefit, but caution is needed if there is an element of cerebral disease as morphine may further impair consciousness and increase the risk of inhalation of vomit.
Prevention
The Himalayan Rescue Association, centred in Kathmandu, has been educating the trekking companies and the trekking public by means of a leaflet in various languages which describes the features of altitude sickness and steps to be taken if it occurs.
It also gives recommended schedules for some of the main routes. However, it is almost impossible to devise a schedule that will be safe for everyone in view of the enormous variation in susceptibility to altitude effects. The most important recommendation is the one advising that people with mild symptoms should go no higher until they have recovered, and those with severe symptoms should go down at once. Thus the more severe forms of the disease may be avoided.
All this valuable propaganda has recently been threatened by the publicity given to the American long distance runner who ran from Kathmandu to Kala Pattar, above the Base Camp of Everest, in 4 days and 14 hours without ill effect. This, though a very fine athletic performance, sets an unfortunate precedent which may affect trekkers as well as potential runners.
Although diuretics, especially acetazolamide and frusemide, have been shown to prevent at least benign AMS, there is no definite evidence that they prevent the malignant forms. Just as rapid descent is the mainstay of treatment, so gradual ascent should be the essential element in preventative advice.
Finally, a rather bizarre case is reported, more on account of the interesting metabolic questions posed than because of any practical relevance to AMS. Many years before, and for unknown reasons, a Post-mortem showed the results of the surgery described above, the expected consequent renal damage and moderate bronchopneumonia affecting both lungs. It seems probable that his death had a metabolic cause in view of the grossly deranged serum electrolytes in the presence of only moderate uraemia.
